Erythropoietin increases asymmetric dimethylarginine in endothelial cells: Role of dimethylarginine dimethylaminohydrolase

Journal of the American Society of Nephrology

Volumn 16, Issue 4, 2005, Pages 892-898

  Scalera, Fortunato ^a   Kielstein, Jan T ^b   Martens Lobenhoffer, Jens ^a   Postel, Sylvia C ^a   Täger, Michael ^c   Bode Böger, Stefanie M ^a,d  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Institute of Medical Technology GmbH   (Germany)

^d UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; DIMETHYLARGININASE; ERYTHROPOIETIN; N(G),N(G) DIMETHYLARGININE; NEUTRALIZING ANTIBODY; NITRATE; NITRIC OXIDE; NITRITE; OXYGEN RADICAL; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; THIOL DERIVATIVE; AMIDASE; ANTIOXIDANT; ARGININE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; RECOMBINANT ERYTHROPOIETIN; THIOCARBAMIC ACID DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; INCUBATION TIME; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; INTRACELLULAR MEMBRANE; METABOLISM; PHYSIOLOGY;

AMIDOHYDROLASES; ANTIOXIDANTS; ARGININE; CELLS, CULTURED; ENDOTHELIAL CELLS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INTRACELLULAR MEMBRANES; NITRIC OXIDE; OXIDATIVE STRESS; PYRROLIDINES; THIOCARBAMATES;

EID: 22844437495     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004090735     Document Type: Article

References (38)

1. Henry DH, Bowers P, Romano MT, Provenzano R: Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 164: 262-276, 2004
2. Macdougall IC: An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16[Suppl 3]: 14-21, 2001
3. Smith KJ, Bleyer AJ, Little WC, Sane DC: The cardiovascular effects of erythropoietin. Cardiovasc Res 59: 538-548, 2003
4. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33: 821-828, 1999
5. Bode-Böger SM, Böger RH, Kuhn M, Radermacher J, Frolich JC: Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 50: 1255-1261, 1996
6. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE: In vivo and in vitro presser effects of erythropoietin in rats. Am J Physiol 269: F838-F845, 1995
7. Wang XQ, Vaziri ND: Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33: 894-899, 1999
8. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor a novel marker of atherosclerosis. Circulation 99: 1141-1146, 1999
9. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Böger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2113-2117, 2001
10. Cooke JP: Asymmetrical dimethylarginine. The Über marker? Circulation 109: 1813-1819, 2004
11. Vallance P, Leiper J: Cardiovascular biology of the asymmetric dimethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24: 1023-1030, 2004
12. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P: Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 119: 1533-1540, 1996
13. Martens-Lobenhoffer J, Bode-Böger SM: Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J Chromatogr B 789: 231-239, 2003
14. Tsikas D, Böger RH, Bode-Böger SM, Gutzki FM, Frolich JC: Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J Chromatogr B 661: 185-191, 1994
15. Lin KY, Ito A, Asagami T, Tsao PS, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP: Impaired nitric oxide synthase pathway in diabetes mellitus. Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106: 987-992, 2002
16. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R: Effect of xantine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure. Results from 2 placebo-controlled studies. Circulation 105: 2619-2624, 2002
17. Dietzmann J, Thiel U, Ansorge S, Neumann KH, Täger M: Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy. Free Radic Biol Med 33: 1347-1354, 2002
18. Li H, Förstermann U: Nitric oxide in the pathogenesis of vascular disease. J Pathol 190: 244-254, 2000
19. Glosh SK, Paik WK, Kim S: Purification and molecular identification of two protein methylases I from calf brain: Myelin basic protein- and histone-specific enzyme. J Biol Chem 263: 19024-19033, 1988
20. Ogawa T, Kimoto M, Sasaoka K: Occurrence of a new enzyme catalyzing the direct conversion of NG, NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 148: 671-677, 1987
21. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343: 209-214, 1999
22. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuhlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP: Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Circulation 108: 1043-1048, 2003
23. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP: Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99: 3092-3095, 1999
24. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP: Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation 104: 2569-2575, 2001
25. Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Täger M, Bode-Böger SM: Endogenous NO-synthesis inhibitor asymmetric dimethyl-L-arginine (ADMA) accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 24: 1816-1822, 2004
26. Chen HC, Tsai JC, Tsai JH, Lai YH: Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis patients. Kidney Int 52: 1390-1394, 1997
27. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B: Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37: 750-757, 2001
28. Usberti M, Gerardi GM, Bufano G, Tira P, Micheli A, Albertini A, Floridi A, Di Lorenzo D, Galli F: Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis 40: 590-599, 2002
29. Hirayama A, Nagase S, Gotoh M, Ueda A, Ishizu T, Yoh K, Aoyagi K, Terao J, Koyama A: Reduced serum hydroxyl radical scavenging activity in erythropoietin therapy resistant renal anemia. Free Radic Res 36: 1155-1161, 2002
30. 2+ channels: Activation by phospholipase C-γ1. Kidney Int 53: 1259-1268, 1998
31. Wilkinson JA, Jacob R: Agonist-induced calcium and oxidative stress responses in endothelial cells. Biochem Soc Trans 31: 960-962, 2003
32. Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant 13[Suppl 2]: 3-8, 1998
33. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr: Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis: Results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis 37: E36, 2001
34. Fischer JW: Erythropoietin: Physiology and pharmacology update. Exp Biol Med 228: 1-14, 2003
35. Eschbach JW: Anemia management in chronic kidney disease: Role of factors affecting epoetin responsiveness. J Am Soc Nephrol 13: 1412-1414, 2002
36. Kang DK, Yoon KI, Han DS: Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant 13: 2877-2883, 1998
37. MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin α in dialysis patients. J Am Soc Nephrol 10: 2392-2395, 1999
38. Kimoto M, Whitley GS, Tsuji H, Ogawa T: Detection of NG, NG-dimethylarginine dimethylaminohydrolase in human tissue using a monoclonal antibody. J Biochem 117: 237-238, 1995